Business Context and Reporting Period
Company: EXICURE, INC. (XCUR)
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2019
Reporting Period: Events occurring on June 26, 2019, and June 27, 2019.
Business Overview: The Company is an emerging growth company focused on preclinical programs in neurology, specifically evaluating spherical nucleic acid constructs.
Key Financial Metrics
This filing is a current report regarding specific corporate events and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material changes to financial position or operations were reported in this filing. The report focuses on the disclosure of new scientific data and corporate communications.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure (Item 7.01): On June 27, 2019, the Company posted a presentation to its website utilized during a conference call to present updates from its preclinical program in neurology.
- Other Events (Item 8.01): On June 26, 2019, the Company issued a press release announcing data from a preclinical study evaluating the biodistribution of spherical nucleic acid constructs in the non-human primate central nervous system.
- Exhibits: The filing includes the presentation (Exhibit 99.1) and the press release (Exhibit 99.2) as attachments.
Investor Verification Checklist
- Review the attached presentation (Exhibit 99.1) for specific details on the preclinical neurology program updates.
- Examine the press release (Exhibit 99.2) for the specific data regarding biodistribution in non-human primates.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm that the information in the exhibits is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.